Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Leukemia

  Free Subscription


Articles published in Ann Hematol

Retrieve available abstracts of 227 articles:
HTML format
Text format



Single Articles


    August 2019
  1. NG DB, Schiller G, Ha E
    Autoimmune hemolytic anemia in refractory hairy cell leukemia on dabrafenib and trametinib.
    Ann Hematol. 2019 Aug 13. pii: 10.1007/s00277-019-03780.
    PubMed     Text format    


  2. KIDOGUCHI K, Kojima K, Yokoo M, Kimura S, et al
    BCR-ABL1- and CBFB-MYH11-positive chronic myeloid leukemia presenting with primary blast crisis and marrow fibrosis.
    Ann Hematol. 2019 Aug 10. pii: 10.1007/s00277-019-03779.
    PubMed     Text format    


  3. GIEBEL S, Boumendil A, Labopin M, Seesaghur A, et al
    Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
    Ann Hematol. 2019 Aug 7. pii: 10.1007/s00277-019-03771.
    PubMed     Text format     Abstract available


  4. SUN YQ, Wang Y, Zhang XH, Xu LP, et al
    Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation.
    Ann Hematol. 2019;98:1877-1883.
    PubMed     Text format     Abstract available


  5. JYOTSANA N, Sharma A, Chaturvedi A, Budida R, et al
    Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.
    Ann Hematol. 2019;98:1905-1918.
    PubMed     Text format     Abstract available


  6. MULLER M, Graf R, Kashofer K, Macher S, et al
    Detection of AML-specific TP53 mutations in bone marrow-derived mesenchymal stromal cells cultured under hypoxia conditions.
    Ann Hematol. 2019;98:2019-2020.
    PubMed     Text format    


  7. MARRA A, Martino G, Ascani S, Martelli MP, et al
    Getting away with phase transition: NPM1-mutated bone myeloid sarcoma mimicking Ewing sarcoma.
    Ann Hematol. 2019;98:2017-2018.
    PubMed     Text format    


    July 2019
  8. SUH KJ, Shin DY, Kim I, Yoon SS, et al
    Comparison of quality of life and health behaviors in survivors of acute leukemia and the general population.
    Ann Hematol. 2019 Jul 23. pii: 10.1007/s00277-019-03760.
    PubMed     Text format     Abstract available


  9. YAMASAKI S, Nitta H, Kondo E, Uchida N, et al
    Effect of allogeneic hematopoietic cell transplantation for patients with T-prolymphocytic leukemia: a retrospective study from the Adult Lymphoma Working Group of the Japan Society for hematopoietic cell transplantation.
    Ann Hematol. 2019 Jul 20. pii: 10.1007/s00277-019-03759.
    PubMed     Text format     Abstract available


  10. JIANG H, Liu L, Guo T, Wu Y, et al
    Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy.
    Ann Hematol. 2019;98:1721-1732.
    PubMed     Text format     Abstract available


  11. STAMOULI M, Gkirkas K, Antoniades A, Kaklamanis L, et al
    Isolated extramedullary leukemic involvement of the heart presenting as fulminant heart failure.
    Ann Hematol. 2019;98:1775-1776.
    PubMed     Text format    


    June 2019
  12. RODRIGUEZ-VEIGA R, Montesinos P, Boluda B, Lorenzo I, et al
    Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.
    Ann Hematol. 2019 Jun 25. pii: 10.1007/s00277-019-03744.
    PubMed     Text format     Abstract available


  13. KAWASHIMA I, Kumagai T, Suzuki M, Suzuki J, et al
    Molecular response of CSF3R T618I harboring chronic neutrophilic leukemia after induction chemotherapy linked to cord blood transplantation.
    Ann Hematol. 2019 Jun 25. pii: 10.1007/s00277-019-03733.
    PubMed     Text format    


  14. REYES-LEON A, Ramirez-Martinez M, Fernandez-Garcia D, Amaro-Munoz D, et al
    Variants in ARID5B gene are associated with the development of acute lymphoblastic leukemia in Mexican children.
    Ann Hematol. 2019 Jun 21. pii: 10.1007/s00277-019-03730.
    PubMed     Text format     Abstract available


  15. YANADA M, Mori J, Aoki J, Masuko M, et al
    Allogeneic hematopoietic cell transplantation for patients with a history of multiple relapses of acute myeloid leukemia.
    Ann Hematol. 2019 Jun 15. pii: 10.1007/s00277-019-03736.
    PubMed     Text format     Abstract available


  16. YE P, Pei R, Jin J, Sun J, et al
    Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2019 Jun 14. pii: 10.1007/s00277-019-03723.
    PubMed     Text format     Abstract available


  17. RAM R, Amit O, Zuckerman T, Gurion R, et al
    Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
    Ann Hematol. 2019 Jun 11. pii: 10.1007/s00277-019-03719.
    PubMed     Text format     Abstract available


  18. BOASMAN K, Simmonds MJ, Graham C, Saunthararajah Y, et al
    Using PU.1 and Jun dimerization protein 2 transcription factor expression in myelodysplastic syndromes to predict treatment response and leukaemia transformation.
    Ann Hematol. 2019;98:1529-1531.
    PubMed     Text format    


  19. MCDONALD L, Fadalla K
    Synchronous follicular non-Hodgkin's lymphoma and hairy cell leukaemia: a case report.
    Ann Hematol. 2019;98:1517-1518.
    PubMed     Text format    


  20. METAFUNI E, Criscuolo M, Spanu T, Sica S, et al
    Ceftazidime-avibactam for gram-negative multidrug-resistant bacteria in hematological patients: a single-center experience.
    Ann Hematol. 2019;98:1495-1497.
    PubMed     Text format    


    May 2019
  21. REN X, Qin Y, Huang X, Zuo L, et al
    Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors.
    Ann Hematol. 2019 May 14. pii: 10.1007/s00277-019-03690.
    PubMed     Text format     Abstract available


  22. MOLICA M, Colafigli G, Scalzulli E, Alunni Fegatelli D, et al
    Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life.
    Ann Hematol. 2019 May 11. pii: 10.1007/s00277-019-03706.
    PubMed     Text format     Abstract available


  23. SHIN HJ, Min WS, Min YH, Cheong JW, et al
    Different prognostic effects of core-binding factor positive AML with Korean AML registry data.
    Ann Hematol. 2019;98:1135-1147.
    PubMed     Text format     Abstract available


  24. MASHIMA K, Ikeda T, Kawaguchi SI, Toda Y, et al
    Comparison of blast percentage calculated based on bone marrow all nucleated cells and non-erythroid cells in myelodysplastic syndromes with erythroid hyperplasia.
    Ann Hematol. 2019;98:1127-1133.
    PubMed     Text format     Abstract available


  25. GARRASTAZUL-SANCHEZ MP, Vilches-Moreno M, Fernandez-Valle MC, Marchante-Cepillo I, et al
    Neutrophil faggot cells and inv(16): not such a fortuitous association?
    Ann Hematol. 2019;98:1293-1295.
    PubMed     Text format    


  26. CAOCCI G, Mulas O, Abruzzese E, Iurlo A, et al
    Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.
    Ann Hematol. 2019 May 1. pii: 10.1007/s00277-019-03705.
    PubMed     Text format     Abstract available


    April 2019
  27. SU L, Gao S, Tan Y, Lin H, et al
    CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations.
    Ann Hematol. 2019 Apr 30. pii: 10.1007/s00277-019-03699.
    PubMed     Text format     Abstract available


  28. AMMATUNA E, Huls G
    Multidimensional radar dot-plots, do we need it for the screening of acute promyelocytic leukemia?
    Ann Hematol. 2019 Apr 25. pii: 10.1007/s00277-019-03693.
    PubMed     Text format    


  29. WANG Z, Yin C, Zhang W, Tang W, et al
    The benefit of chronic graft-versus-host disease in patients with acute myeloid leukemia relapsed after allogeneic stem cell transplantation.
    Ann Hematol. 2019 Apr 16. pii: 10.1007/s00277-019-03682.
    PubMed     Text format     Abstract available


  30. ZHANG X, Guo X
    Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.
    Ann Hematol. 2019 Apr 12. pii: 10.1007/s00277-019-03674.
    PubMed     Text format    


  31. ZHANG YL, Zhu Y, Xiao Q, Wang L, et al
    Cytomegalovirus infection is associated with AML relapse after allo-HSCT: a meta-analysis of observational studies.
    Ann Hematol. 2019;98:1009-1020.
    PubMed     Text format     Abstract available


  32. BIANCHI M, Heim D, Lengerke C, Halter J, et al
    Cyclosporine levels > 195 mug/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2019;98:971-977.
    PubMed     Text format     Abstract available


  33. XHAARD A, Porcher R, Bergeron A, Alanio A, et al
    Primary antifungal prophylaxis with micafungin after allogeneic hematopoietic stem cell transplantation: a monocentric prospective study.
    Ann Hematol. 2019;98:1033-1035.
    PubMed     Text format    


    March 2019
  34. HELBIG G, Spalek A, Wieczorkiewicz-Kabut A, Markiewicz M, et al
    Allogeneic transplantation for high-risk chronic lymphocytic leukemia-a summary of a 16-year experience.
    Ann Hematol. 2019 Mar 27. pii: 10.1007/s00277-019-03679.
    PubMed     Text format     Abstract available


  35. LINS MM, Mello MJG, Ribeiro RC, De Camargo B, et al
    Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low-middle-income country.
    Ann Hematol. 2019 Mar 26. pii: 10.1007/s00277-019-03661.
    PubMed     Text format     Abstract available


  36. KONISHI T, Doki N, Kishida Y, Nagata A, et al
    Geriatric nutritional risk index (GNRI) just before allogeneic hematopoietic stem cell transplantation predicts transplant outcomes in patients older than 50 years with acute myeloid leukemia in complete remission.
    Ann Hematol. 2019 Mar 21. pii: 10.1007/s00277-019-03668.
    PubMed     Text format    


  37. KESSLER T, Koschmieder S, Schliemann C, Crysandt M, et al
    Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML).
    Ann Hematol. 2019 Mar 21. pii: 10.1007/s00277-019-03651.
    PubMed     Text format     Abstract available


  38. GAJENDRA S, Yadav AK, Chugh B, Sood N, et al
    Clinicohematologic and cytogenetic profile in a rare case of pure erythroid leukemia.
    Ann Hematol. 2019 Mar 11. pii: 10.1007/s00277-019-03660.
    PubMed     Text format    


  39. KARAI B, Habok M, Remenyi G, Rejto L, et al
    A novel flow cytometric method for enhancing acute promyelocytic leukemia screening by multidimensional dot-plots.
    Ann Hematol. 2019 Mar 4. pii: 10.1007/s00277-019-03642.
    PubMed     Text format     Abstract available


  40. KUNZ F, Kontopoulou E, Reinhardt K, Soldierer M, et al
    Detection of AML-specific mutations in pediatric patient plasma using extracellular vesicle-derived RNA.
    Ann Hematol. 2019;98:595-603.
    PubMed     Text format     Abstract available


  41. OYAKE T, Takemasa-Fujisawa Y, Sugawara N, Mine T, et al
    Doripenem versus meropenem as first-line empiric therapy of febrile neutropenia in patients with acute leukemia: a prospective, randomized study.
    Ann Hematol. 2019 Mar 1. pii: 10.1007/s00277-019-03634.
    PubMed     Text format     Abstract available


    February 2019
  42. DULUCQ S, Etienne G, Morisset S, Klein E, et al
    Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.
    Ann Hematol. 2019 Feb 23. pii: 10.1007/s00277-019-03633.
    PubMed     Text format     Abstract available


  43. YSEBAERT L, Larcher M, Compaci G, Oberic L, et al
    Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic leukemia.
    Ann Hematol. 2019 Feb 18. pii: 10.1007/s00277-019-03631.
    PubMed     Text format     Abstract available


  44. XIE W, Hu S, Xu J, Chen Z, et al
    Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adults.
    Ann Hematol. 2019 Feb 13. pii: 10.1007/s00277-019-03637.
    PubMed     Text format     Abstract available


  45. GAO XN, Lin J, Wang LJ, Li F, et al
    Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.
    Ann Hematol. 2019 Feb 12. pii: 10.1007/s00277-019-03636.
    PubMed     Text format     Abstract available


  46. MINA A, Shune L, Abdelhakim H, Lin TL, et al
    Long-term results of a pilot study evaluating hyperbaric oxygen therapy to improve umbilical cord blood engraftment.
    Ann Hematol. 2019;98:481-489.
    PubMed     Text format     Abstract available


  47. PICARDI M, Della Pepa R, Giordano C, Pugliese N, et al
    (1-3)-beta-D-Glucan serum increase and small-airway-invasive radiological findings as early signs of pulmonary aspergillosis in high-risk hematologic patients in the posaconazole era: preliminary observations.
    Ann Hematol. 2019;98:527-531.
    PubMed     Text format    


    January 2019
  48. KANAKASETTY GB, R C, K C L, Dasappa L, et al
    Treatment patterns and comparative analysis of non-intensive regimens in elderly acute myeloid leukemia patients-a real-world experience from India.
    Ann Hematol. 2019 Jan 29. pii: 10.1007/s00277-019-03600.
    PubMed     Text format     Abstract available


  49. CHEUNG E, Perissinotti AJ, Bixby DL, Burke PW, et al
    The leukemia strikes back: a review of pathogenesis and treatment of secondary AML.
    Ann Hematol. 2019 Jan 21. pii: 10.1007/s00277-019-03606.
    PubMed     Text format     Abstract available


  50. OKUYAMA S, Nito T, Yanagawa N, Tajima K, et al
    Giant cellulitis-like Sweet syndrome as an initial clinical presentation of acute myeloblastic leukemia with t(6;9)(p23;q34): DEK-CAN and internal duplications of FMS-like tyrosine kinase 3.
    Ann Hematol. 2019 Jan 18. pii: 10.1007/s00277-019-03613.
    PubMed     Text format    


  51. LIU B, Wang Y, Zhou C, Wei H, et al
    Nilotinib combined with multi-agent chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center prospective study with long-term follow-up.
    Ann Hematol. 2019 Jan 11. pii: 10.1007/s00277-019-03594.
    PubMed     Text format     Abstract available


  52. LIU L, Zhang X, Qiu H, Tang X, et al
    HLA-mismatched stem cell microtransplantation compared to matched-sibling donor transplantation for intermediate/high-risk acute myeloid leukemia.
    Ann Hematol. 2019 Jan 10. pii: 10.1007/s00277-018-3583.
    PubMed     Text format     Abstract available


  53. DOPPELHAMMER M, Fraccaroli A, Prevalsek D, Bucklein V, et al
    Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis.
    Ann Hematol. 2019 Jan 8. pii: 10.1007/s00277-019-03593.
    PubMed     Text format     Abstract available


  54. STRATMANN JA, von Rose AB, Koschade S, Wendelin K, et al
    Clinical and genetic characterization of de novo double-hit B cell precursor leukemia/lymphoma.
    Ann Hematol. 2019 Jan 6. pii: 10.1007/s00277-018-03590.
    PubMed     Text format     Abstract available


  55. ZHANG Y, Zhang Y, Chen Q, Tang G, et al
    Allogeneic hematopoietic stem cells transplantation improves the survival of intermediate-risk acute myeloid leukemia patients aged less than 60 years.
    Ann Hematol. 2019 Jan 3. pii: 10.1007/s00277-018-3584.
    PubMed     Text format     Abstract available


  56. KAWASHIMA N, Akashi A, Nagata Y, Kihara R, et al
    Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.
    Ann Hematol. 2019;98:83-91.
    PubMed     Text format     Abstract available


  57. XIAOSU Z, Leqing C, Yazhen Q, Yu W, et al
    Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFbeta/MYH11 gene expression.
    Ann Hematol. 2019;98:73-81.
    PubMed     Text format     Abstract available


  58. GAO XN, Lin J, Wang SH, Huang WR, et al
    Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies.
    Ann Hematol. 2019;98:185-193.
    PubMed     Text format     Abstract available


  59. WANNER D, Bohn JP, Rudzki J, Stockhammer G, et al
    Autoimmune myelitis in a CLL patient undergoing treatment with ibrutinib.
    Ann Hematol. 2019;98:205-207.
    PubMed     Text format    


    December 2018
  60. BUCCHERI V, Barreto WG, Fogliatto LM, Capra M, et al
    Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
    Ann Hematol. 2018;97:2269-2278.
    PubMed     Text format     Abstract available


  61. CASTELLI R, Rossi V, Della Porta MG, Schiavon R, et al
    Clinical characteristics and treatment outcome of an 86-year-old patient with acute myeloid leukaemia with acute promyelocytic-like morphology and uncommon RARA fusion variant.
    Ann Hematol. 2018;97:2523-2525.
    PubMed     Text format    


    November 2018
  62. QASRAWI A, Bahaj W, Qasrawi L, Abughanimeh O, et al
    Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?
    Ann Hematol. 2018 Nov 23. pii: 10.1007/s00277-018-3562.
    PubMed     Text format     Abstract available


  63. ISHIDA H, Iguchi A, Aoe M, Takahashi T, et al
    Panel-based next-generation sequencing identifies prognostic and actionable genes in childhood acute lymphoblastic leukemia and is suitable for clinical sequencing.
    Ann Hematol. 2018 Nov 17. pii: 10.1007/s00277-018-3554.
    PubMed     Text format     Abstract available


  64. DE BARROS S, Vayr F, Despas F, Strumia M, et al
    The impact of chronic myeloid leukemia on employment: the French prospective study.
    Ann Hematol. 2018 Nov 17. pii: 10.1007/s00277-018-3549.
    PubMed     Text format     Abstract available


  65. GARCIA-GUTIERREZ V, Milojkovic D, Hernandez-Boluda JC, Claudiani S, et al
    Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
    Ann Hematol. 2018 Nov 16. pii: 10.1007/s00277-018-3507.
    PubMed     Text format     Abstract available


  66. PEJSA V, Lucijanic M, Jonjic Z, Prka Z, et al
    Progressive multifocal leukoencephalopathy developing after obinutuzumab treatment for chronic lymphocytic leukemia.
    Ann Hematol. 2018 Nov 13. pii: 10.1007/s00277-018-3552.
    PubMed     Text format    


  67. BODDU P, Chihara D, Masarova L, Pemmaraju N, et al
    The co-occurrence of driver mutations in chronic myeloproliferative neoplasms.
    Ann Hematol. 2018;97:2071-2080.
    PubMed     Text format     Abstract available


  68. SHALLIS RM, Xu ML, Curtis SA, Medoff E, et al
    Conviction in the face of affliction: a case series of Jehovah's Witnesses with myeloid malignancies.
    Ann Hematol. 2018;97:2245-2248.
    PubMed     Text format    


  69. BRUNELLO L, Passera R, Dellacasa CM, Giaccone L, et al
    Haplo-identical allografting with post-transplant cyclophosphamide in high-risk patients.
    Ann Hematol. 2018;97:2205-2215.
    PubMed     Text format     Abstract available


    October 2018
  70. LI Y, Shao H, Fu B
    Coexistence of t(5;17)/NPM1-RARA and t(9;22)/BCR-ABL1 in chronic myeloid leukemia at initial diagnosis.
    Ann Hematol. 2018 Oct 30. pii: 10.1007/s00277-018-3537.
    PubMed     Text format    


  71. ZAPRAZNA K, Reblova K, Svobodova V, Radova L, et al
    Activation-induced deaminase and its splice variants associate with trisomy 12 in chronic lymphocytic leukemia.
    Ann Hematol. 2018 Oct 27. pii: 10.1007/s00277-018-3520.
    PubMed     Text format     Abstract available


  72. NAKAMURA N, Ninomiya S, Matsumoto T, Nakamura H, et al
    Prognostic impact of skeletal muscle assessed by computed tomography in patients with acute myeloid leukemia.
    Ann Hematol. 2018 Oct 19. pii: 10.1007/s00277-018-3508.
    PubMed     Text format     Abstract available


  73. RANI L, Gogia A, Singh V, Kumar L, et al
    Comparative assessment of prognostic models in chronic lymphocytic leukemia: evaluation in Indian cohort.
    Ann Hematol. 2018 Oct 18. pii: 10.1007/s00277-018-3525.
    PubMed     Text format     Abstract available


  74. LEE AC, Leo SW
    Juvenile myelomonocytic leukemia: a surprising cause of peri-orbital tumor and squint.
    Ann Hematol. 2018 Oct 12. pii: 10.1007/s00277-018-3510.
    PubMed     Text format    


  75. KHALIL MMI, Messner HA, Lipton JH, Kim DD, et al
    Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies.
    Ann Hematol. 2018;97:1975-1985.
    PubMed     Text format     Abstract available


  76. EGLE A, Steurer M, Melchardt T, Weiss L, et al
    Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
    Ann Hematol. 2018;97:1825-1839.
    PubMed     Text format     Abstract available


  77. FORBRIGGER Z, Kuhle S, Brown MM, Moorehead PC, et al
    The association of venous thromboembolism with survival in pediatric cancer patients: a population-based cohort study.
    Ann Hematol. 2018;97:1903-1908.
    PubMed     Text format     Abstract available


  78. BARON F, Stevens-Kroef M, Kicinski M, Meloni G, et al
    Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials.
    Ann Hematol. 2018;97:1785-1795.
    PubMed     Text format     Abstract available


  79. BARONI F, Marraccini C, Merolle L, Piccagli V, et al
    Red blood cells metabolome changes upon treatment with different X-ray irradiation doses.
    Ann Hematol. 2018;97:1909-1917.
    PubMed     Text format     Abstract available


  80. ISOBE Y, Uemura Y, Uchida A, Miura I, et al
    A portion of expanded granular lymphocytes cause pure white cell aplasia?
    Ann Hematol. 2018;97:1995-1997.
    PubMed     Text format    


    September 2018
  81. URESHINO H, Kusaba K, Kidoguchi K, Sano H, et al
    Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma.
    Ann Hematol. 2018 Sep 27. pii: 10.1007/s00277-018-3502.
    PubMed     Text format     Abstract available


  82. JUNG SH, Lee SR, Yang DH, Lee S, et al
    Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party.
    Ann Hematol. 2018 Sep 26. pii: 10.1007/s00277-018-3495.
    PubMed     Text format     Abstract available


  83. STEIN AS, Schiller G, Benjamin R, Jia C, et al
    Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors.
    Ann Hematol. 2018 Sep 20. pii: 10.1007/s00277-018-3497.
    PubMed     Text format     Abstract available


  84. VAN DE LOUW A, Lewis AM, Yang Z
    Autopsy findings in patients with acute myeloid leukemia and non-Hodgkin lymphoma in the modern era: a focus on lung pathology and acute respiratory failure.
    Ann Hematol. 2018 Sep 14. pii: 10.1007/s00277-018-3494.
    PubMed     Text format     Abstract available


  85. ELBAEK MV, Sorensen AL, Hasselbalch HC
    Cardiovascular disease in chronic myelomonocytic leukemia: do monocytosis and chronic inflammation predispose to accelerated atherosclerosis?
    Ann Hematol. 2018 Sep 4. pii: 10.1007/s00277-018-3489.
    PubMed     Text format     Abstract available


  86. TIMMERS NKLM, de Maar JS, van Kruijsdijk RCM, Klein SK, et al
    Central nervous system localisation of chronic lymphocytic leukaemia, description of two very distinct cases and a review of the literature.
    Ann Hematol. 2018;97:1627-1632.
    PubMed     Text format     Abstract available


  87. HATTA Y, Mizuta S, Matsuo K, Ohtake S, et al
    Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.
    Ann Hematol. 2018;97:1535-1545.
    PubMed     Text format     Abstract available


    August 2018
  88. WANG H, Li Y, Lv N, Li Y, et al
    Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes.
    Ann Hematol. 2018 Aug 6. pii: 10.1007/s00277-018-3464.
    PubMed     Text format     Abstract available


  89. SCHULER E, Zadrozny N, Blum S, Schroeder T, et al
    Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy.
    Ann Hematol. 2018 Aug 4. pii: 10.1007/s00277-018-3466.
    PubMed     Text format     Abstract available


  90. XIAO H, Li L, Pang Y, Wu Y, et al
    Sequential treatment combining cladribine-based re-induction, myeloablative allogeneic HSCT, and prophylactic donor lymphocyte infusion: a promising treatment for refractory acute myeloid leukemia.
    Ann Hematol. 2018 Aug 4. pii: 10.1007/s00277-018-3453.
    PubMed     Text format     Abstract available


  91. MONTORO J, Gallur L, Merchan B, Molero A, et al
    Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes.
    Ann Hematol. 2018;97:1349-1356.
    PubMed     Text format     Abstract available


  92. DE ALVARENGA EC, Silva WN, Vasconcellos R, Paredes-Gamero EJ, et al
    Promyelocytic leukemia protein in mesenchymal stem cells is essential for leukemia progression.
    Ann Hematol. 2018 Aug 1. pii: 10.1007/s00277-018-3463.
    PubMed     Text format     Abstract available


  93. PINTO AL, Ferreira G, Carda JP, Gomes M, et al
    Isolated Richter's syndrome of the brain: diagnosis in the eye of the beholder.
    Ann Hematol. 2018;97:1509-1511.
    PubMed     Text format    


  94. CASTELLI A, Mosca-Siez ML, Riccomagno P, Patriarca A, et al
    Efficacy and safety of decitabine against cutaneous granuloblastic sarcoma: a case report.
    Ann Hematol. 2018;97:1485-1486.
    PubMed     Text format    


  95. FUREDER W, Sperr WR, Gleixner K, Thalhammer R, et al
    Major response of PNH to an AML chemotherapy protocol.
    Ann Hematol. 2018;97:1487-1488.
    PubMed     Text format    


  96. JIN Z, Xiang R, Qing K, Li X, et al
    The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
    Ann Hematol. 2018;97:1327-1335.
    PubMed     Text format     Abstract available


    July 2018
  97. SCHNEIDAWIND C, Hagmaier V, Faul C, Kanz L, et al
    Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia.
    Ann Hematol. 2018 Jul 31. pii: 10.1007/s00277-018-3454.
    PubMed     Text format     Abstract available


  98. GU B, Zhang X, Chen G, Wu X, et al
    Efficacy of haploidentical hematopoietic stem cell transplantation compared to HLA-matched transplantation for primary refractory acute myeloid leukemia.
    Ann Hematol. 2018 Jul 23. pii: 10.1007/s00277-018-3428.
    PubMed     Text format     Abstract available


  99. PARK E, Jue MS
    Radotinib-induced eruptive melanocytic nevi in patient with chronic myeloid leukemia: a case report and literature review.
    Ann Hematol. 2018 Jul 21. pii: 10.1007/s00277-018-3444.
    PubMed     Text format    


  100. BURNS TF, Loo EY, Bengtson EM, Bao L, et al
    Cytogenetically cryptic insertion of PML segment into RARA on chromosome 17q resulting PML-RARA fusion in acute promyelocytic leukemia.
    Ann Hematol. 2018 Jul 20. pii: 10.1007/s00277-018-3399.
    PubMed     Text format    


  101. ZHANG G, Zhang L, Yang X, Zhang X, et al
    High ETS2 expression predicts poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2018 Jul 18. pii: 10.1007/s00277-018-3440.
    PubMed     Text format    


  102. ZAPPASODI P, Marbello L, Borlenghi E, Fumagalli M, et al
    Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network.
    Ann Hematol. 2018 Jul 15. pii: 10.1007/s00277-018-3424.
    PubMed     Text format     Abstract available


  103. LIN XJ, Dai HP, Wang AJ, Chen F, et al
    Effects of preemptive interferon-alpha monotherapy in acute leukemia patients with relapse tendency after allogeneic hematopoietic stem cell transplantation: a case-control study.
    Ann Hematol. 2018 Jul 11. pii: 10.1007/s00277-018-3429.
    PubMed     Text format     Abstract available


  104. DUGGE R, Kreipe H, Rosenwald A, Lehmann U, et al
    Coincidence of lymphomatoid granulomatosis, chronic myelomonocytic leukemia, and anaplastic T cell lymphoma after methotrexate therapy for rheumatoid arthritis.
    Ann Hematol. 2018 Jul 7. pii: 10.1007/s00277-018-3434.
    PubMed     Text format    


  105. KONUMA T, Mizuno S, Kondo T, Yamaguchi H, et al
    Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).
    Ann Hematol. 2018 Jul 6. pii: 10.1007/s00277-018-3419.
    PubMed     Text format     Abstract available


  106. SUEDA S, Nakayama S, Adachi T, Ohashi Y, et al
    Cytotoxic T-lymphocyte-associated antigen 4-positive aggressive adult T cell leukemia/lymphoma.
    Ann Hematol. 2018 Jul 6. pii: 10.1007/s00277-018-3426.
    PubMed     Text format    


  107. MEGIAS-VERICAT JE, Martinez-Cuadron D, Sanz MA, Montesinos P, et al
    Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review.
    Ann Hematol. 2018;97:1115-1153.
    PubMed     Text format     Abstract available


  108. VANDER MEEREN S, Heyrman B, Renmans W, Bakkus M, et al
    Lymphoma-like monoclonal B cell lymphocytosis in a patient population: biology, natural evolution, and differences from CLL-like clones.
    Ann Hematol. 2018;97:1219-1227.
    PubMed     Text format     Abstract available


    June 2018
  109. KRISTON C, Plander M, Mark A, Sebestyen A, et al
    In contrast to high CD49d, low CXCR4 expression indicates the dependency of chronic lymphocytic leukemia (CLL) cells on the microenvironment.
    Ann Hematol. 2018 Jun 28. pii: 10.1007/s00277-018-3410.
    PubMed     Text format     Abstract available


  110. OSORIO S, Escudero-Vilaplana V, Gomez-Centurion I, Perez-Lopez R, et al
    Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
    Ann Hematol. 2018 Jun 28. pii: 10.1007/s00277-018-3413.
    PubMed     Text format     Abstract available


  111. KUBOTA Y, Kamachi K, Wakayama K, Kitamura H, et al
    Acute myeloid leukemia with t(19;21)(q13;q22) and marked eosinophilia.
    Ann Hematol. 2018 Jun 27. pii: 10.1007/s00277-018-3408.
    PubMed     Text format    


  112. CICCONI L, Breccia M, Franceschini L, Latagliata R, et al
    Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
    Ann Hematol. 2018 Jun 27. pii: 10.1007/s00277-018-3400.
    PubMed     Text format     Abstract available


  113. FUJIOKA I, Takaku T, Iriyama N, Tokuhira M, et al
    Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database.
    Ann Hematol. 2018 Jun 26. pii: 10.1007/s00277-018-3412.
    PubMed     Text format     Abstract available


  114. STRUGOV V, Stadnik E, Virts Y, Andreeva T, et al
    Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia.
    Ann Hematol. 2018 Jun 26. pii: 10.1007/s00277-018-3409.
    PubMed     Text format     Abstract available


  115. ZHU Y, Gao Q, Du J, Hu J, et al
    Effects of post-remission chemotherapy before allo-HSCT for acute myeloid leukemia during first complete remission: a meta-analysis.
    Ann Hematol. 2018 Jun 26. pii: 10.1007/s00277-018-3414.
    PubMed     Text format     Abstract available


  116. FEDERMANN B, Mueller MR, Steinhilber J, Horger MS, et al
    Diagnosis of Richter transformation in chronic lymphocytic leukemia: histology tips the scales.
    Ann Hematol. 2018 Jun 12. pii: 10.1007/s00277-018-3390.
    PubMed     Text format     Abstract available


  117. MAURILLO L, Buccisano F, Spagnoli A, Voso MT, et al
    Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.
    Ann Hematol. 2018 Jun 10. pii: 10.1007/s00277-018-3374.
    PubMed     Text format     Abstract available


  118. LIU H, Wang SA, Schlette EJ, Xu J, et al
    Myeloid neoplasms with t(16;21)(q24;q22)/RUNX1-RUNX1T3 mimics acute myeloid leukemia with RUNX1-RUNX1T1.
    Ann Hematol. 2018 Jun 5. pii: 10.1007/s00277-018-3389.
    PubMed     Text format     Abstract available


  119. SAKELLARI I, Gavriilaki E, Chatziioannou K, Papathanasiou M, et al
    Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study.
    Ann Hematol. 2018 Jun 5. pii: 10.1007/s00277-018-3383.
    PubMed     Text format     Abstract available


  120. SAHIN U, Dalva K, Gungor F, Ustun C, et al
    Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
    Ann Hematol. 2018;97:1027-1039.
    PubMed     Text format     Abstract available


  121. ZERKALENKOVA E, Panfyorova A, Kazakova A, Baryshev P, et al
    Molecular characteristic of acute leukemias with t(16;21)/FUS-ERG.
    Ann Hematol. 2018;97:977-988.
    PubMed     Text format     Abstract available


  122. ZHAO X, Wang Z, Ruan G, Liu Y, et al
    Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation.
    Ann Hematol. 2018;97:967-975.
    PubMed     Text format     Abstract available


  123. STRENGER V, Merth G, Lackner H, Aberle SW, et al
    Malignancy and chemotherapy induced haemophagocytic lymphohistiocytosis in children and adolescents-a single centre experience of 20 years.
    Ann Hematol. 2018;97:989-998.
    PubMed     Text format     Abstract available


  124. ZAUNER F, Tayeb S, Panagiota V, Rababah M, et al
    Acquired long QT syndrome during conditioning for allogeneic stem cell transplantation-are we aware of this side effect?
    Ann Hematol. 2018;97:1111-1113.
    PubMed     Text format    


    May 2018
  125. IWASHIGE A, Hirosawa M, Tsukada J
    Hairy cell leukemia presenting with progressive pericarditis and pleuritis.
    Ann Hematol. 2018 May 30. pii: 10.1007/s00277-018-3378.
    PubMed     Text format    


  126. MOLICA M, Scalzulli E, Colafigli G, Fegatelli DA, et al
    Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.
    Ann Hematol. 2018 May 27. pii: 10.1007/s00277-018-3375.
    PubMed     Text format     Abstract available


  127. BILL M, Grimm J, Jentzsch M, Kloss L, et al
    Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
    Ann Hematol. 2018 May 22. pii: 10.1007/s00277-018-3373.
    PubMed     Text format     Abstract available


  128. ALLAIN EP, Venzl K, Caron P, Turcotte V, et al
    Sex-dependent association of circulating sex steroids and pituitary hormones with treatment-free survival in chronic lymphocytic leukemia patients.
    Ann Hematol. 2018 May 21. pii: 10.1007/s00277-018-3356.
    PubMed     Text format     Abstract available


  129. MOLICA S, Giannarelli D, Mirabelli R, Levato L, et al
    Chronic lymphocytic leukemia international prognostic index (CLL-IPI) in patients receiving chemoimmuno or targeted therapy: a systematic review and meta-analysis.
    Ann Hematol. 2018 May 8. pii: 10.1007/s00277-018-3350.
    PubMed     Text format    


  130. MIAO Y, Miao Y, Shi K, Sun Q, et al
    A higher percentage of cells with 13q deletion predicts worse outcome in Chinese patients with chronic lymphocytic leukemia carrying isolated 13q deletion.
    Ann Hematol. 2018 May 7. pii: 10.1007/s00277-018-3359.
    PubMed     Text format     Abstract available


  131. MARHALL A, Heidel F, Fischer T, Ronnstrand L, et al
    Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
    Ann Hematol. 2018;97:773-780.
    PubMed     Text format     Abstract available


  132. VIGNOLI A, Marchetti M, Falanga A
    Acute promyelocytic leukemia cell adhesion to vascular endothelium is reduced by heparins.
    Ann Hematol. 2018 May 1. pii: 10.1007/s00277-018-3343.
    PubMed     Text format     Abstract available


    April 2018
  133. HONG Y, Zhao X, Qin Y, Zhou S, et al
    The prognostic role of E2A-PBX1 expression detected by real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) in B cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2018 Apr 28. pii: 10.1007/s00277-018-3338.
    PubMed     Text format     Abstract available


  134. COLTOFF A, Houldsworth J, Keyzner A, Renteria AS, et al
    Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
    Ann Hematol. 2018 Apr 27. pii: 10.1007/s00277-018-3330.
    PubMed     Text format     Abstract available


  135. ZHANG J, Shi J, Zhang G, Zhang X, et al
    BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2018 Apr 25. pii: 10.1007/s00277-018-3331.
    PubMed     Text format     Abstract available


  136. ZHANG X, Li B, Yu J, Dahlstrom J, et al
    Correction to: MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia.
    Ann Hematol. 2018 Apr 25. pii: 10.1007/s00277-018-3340.
    PubMed     Text format     Abstract available


  137. BRECCIA M, Abruzzese E, Castagnetti F, Bonifacio M, et al
    Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice.
    Ann Hematol. 2018 Apr 19. pii: 10.1007/s00277-018-3337.
    PubMed     Text format     Abstract available


  138. WANG X, Zhang L, Zhao F, Xu R, et al
    Long non-coding RNA taurine-upregulated gene 1 correlates with poor prognosis, induces cell proliferation, and represses cell apoptosis via targeting aurora kinase A in adult acute myeloid leukemia.
    Ann Hematol. 2018 Apr 13. pii: 10.1007/s00277-018-3315.
    PubMed     Text format     Abstract available


  139. LO WJ, Lin CL, Chang YC, Bai LY, et al
    Total body irradiation tremendously impair the proliferation, differentiation and chromosomal integrity of bone marrow-derived mesenchymal stromal stem cells.
    Ann Hematol. 2018;97:697-707.
    PubMed     Text format     Abstract available


  140. SCAPPATICCI GB, Marini BL, Nachar VR, Uebel JR, et al
    Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG.
    Ann Hematol. 2018;97:573-584.
    PubMed     Text format     Abstract available


    March 2018
  141. SUZUKI Y, Honda A, Nakazaki K, Mizuno H, et al
    Histological transformation of MALT lymphoma to plasma cell leukemia after rituximab-containing therapy.
    Ann Hematol. 2018 Mar 26. pii: 10.1007/s00277-018-3300.
    PubMed     Text format    


  142. SAINI NY, Bathini V
    Large granular lymphocytic leukemia-associated peripheral neuropathy.
    Ann Hematol. 2018 Mar 22. pii: 10.1007/s00277-018-3310.
    PubMed     Text format    


  143. KHAN M, Muzzafar T, Kantarjian H, Badar I, et al
    Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.
    Ann Hematol. 2018 Mar 20. pii: 10.1007/s00277-018-3289.
    PubMed     Text format     Abstract available


  144. PIATOPOULOU D, Avgeris M, Drakaki I, Marmarinos A, et al
    Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
    Ann Hematol. 2018 Mar 20. pii: 10.1007/s00277-018-3292.
    PubMed     Text format     Abstract available


  145. KIM DW, Saussele S, Williams LA, Mohamed H, et al
    Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study.
    Ann Hematol. 2018 Mar 20. pii: 10.1007/s00277-018-3295.
    PubMed     Text format     Abstract available


  146. KHAN M, Siddiqi R, Naqvi K
    An update on classification, genetics, and clinical approach to mixed phenotype acute leukemia (MPAL).
    Ann Hematol. 2018 Mar 15. pii: 10.1007/s00277-018-3297.
    PubMed     Text format     Abstract available


  147. HA J, Kim B, Hahn S, Lee ST, et al
    A patient with B-cell acute lymphoblastic leukemia with PAX5-ETV6 rearrangement with dic(9;12)(p13;p13) identified by chromosomal microarray.
    Ann Hematol. 2018 Mar 8. pii: 10.1007/s00277-018-3291.
    PubMed     Text format    


  148. PARK S, Choi H, Kim HJ, Ahn JS, et al
    Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients.
    Ann Hematol. 2018 Mar 2. pii: 10.1007/s00277-018-3260.
    PubMed     Text format     Abstract available


  149. HIDALGO LOPEZ JE, Carballo-Zarate A, Verstovsek S, Wang SA, et al
    Bone marrow findings in blast phase of polycythemia vera.
    Ann Hematol. 2018;97:425-434.
    PubMed     Text format     Abstract available


  150. HARADA K, Doki N, Miyazaki Y, Wakita A, et al
    Clinical impact of underweight status at diagnosis on elderly patients with acute myeloid leukemia: a retrospective study of JALSG GML200.
    Ann Hematol. 2018 Mar 1. pii: 10.1007/s00277-018-3281.
    PubMed     Text format    


    February 2018
  151. MARTINEZ-CUADRON D, Boluda B, Martinez P, Bergua J, et al
    Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
    Ann Hematol. 2018 Feb 23. pii: 10.1007/s00277-018-3277.
    PubMed     Text format     Abstract available


  152. BRECCIA M, Palandri F, Luciano L, Benevolo G, et al
    Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment.
    Ann Hematol. 2018 Feb 22. pii: 10.1007/s00277-018-3258.
    PubMed     Text format     Abstract available


  153. SHIMOMURA Y, Hara M, Katoh D, Hashimoto H, et al
    Enlarged spleen is associated with low neutrophil and platelet engraftment rates and poor survival after allogeneic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Ann Hematol. 2018 Feb 17. pii: 10.1007/s00277-018-3278.
    PubMed     Text format     Abstract available


  154. ZHAO HY, Song Y, Cao XN, Qin YZ, et al
    Leukemia-propagating cells demonstrate distinctive gene expression profiles compared with other cell fractions from patients with de novo Philadelphia chromosome-positive ALL.
    Ann Hematol. 2018 Feb 10. pii: 10.1007/s00277-018-3253.
    PubMed     Text format     Abstract available


  155. NAKAYAMA S, Matsuda M, Adachi T, Sueda S, et al
    Adult T cell leukemia/lymphoma with different pathological features in each tumor site.
    Ann Hematol. 2018 Feb 9. pii: 10.1007/s00277-018-3272.
    PubMed     Text format    


  156. SUZUKI Y, Koya J, Ebisawa K, Abe H, et al
    Sequential development of monoclonal B cell lymphocytosis-derived small lymphocytic lymphoma and plasma cell leukemia.
    Ann Hematol. 2018 Feb 7. pii: 10.1007/s00277-018-3248.
    PubMed     Text format    


  157. WEI G, Hu Y, Pu C, Yu J, et al
    CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study.
    Ann Hematol. 2018 Feb 7. pii: 10.1007/s00277-018-3246.
    PubMed     Text format     Abstract available


  158. DI BLASI R, Cattaneo C, Lewis RE, Tumbarello M, et al
    Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL).
    Ann Hematol. 2018 Feb 7. pii: 10.1007/s00277-018-3252.
    PubMed     Text format     Abstract available


  159. TACHIKI L, Dong ZM, Burwick N
    Atypical chronic lymphocytic leukemia presenting with massive IgM paraprotein.
    Ann Hematol. 2018 Feb 6. pii: 10.1007/s00277-018-3261.
    PubMed     Text format    


  160. MORITA K, Koya J, Toya T, Nakamura F, et al
    Philadelphia chromosome-negative acute promyelocytic leukemia manifesting after long-term imatinib treatment for chronic myeloid leukemia: a case report and literature review.
    Ann Hematol. 2018 Feb 6. pii: 10.1007/s00277-018-3263.
    PubMed     Text format    


  161. FUJIMI A, Nagamachi Y, Yamauchi N
    Extramedullary involvement of the stomach presenting as multiple white elevations in the initial diagnosis of chronic myeloid leukemia treated with dasatinib.
    Ann Hematol. 2018 Feb 6. pii: 10.1007/s00277-018-3268.
    PubMed     Text format    


  162. MARTINEZ-CUADRON D, Boluda B, Martinez P, Bergua J, et al
    A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
    Ann Hematol. 2018 Feb 2. pii: 10.1007/s00277-018-3229.
    PubMed     Text format     Abstract available


  163. MELLINGHOFF SC, Panse J, Alakel N, Behre G, et al
    Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
    Ann Hematol. 2018;97:197-207.
    PubMed     Text format     Abstract available


  164. DUONG VH, Padron E, Al Ali NH, Lancet JE, et al
    The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.
    Ann Hematol. 2018;97:247-254.
    PubMed     Text format     Abstract available


  165. SCHROEDER T, Rautenberg C, Kruger W, Platzbecker U, et al
    Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Ann Hematol. 2018;97:335-342.
    PubMed     Text format     Abstract available


  166. MINODA S, Akasaka T, Okanoue Y, Honjo G, et al
    Relapse of acute promyelocytic leukemia in the external auditory canal confirmed by PML/RARA dual-fusion and RARA break-apart fluorescence in situ hybridization.
    Ann Hematol. 2018 Feb 1. pii: 10.1007/s00277-018-3235.
    PubMed     Text format    


  167. SHAHKARAMI S, Mehrasa R, Younesian S, Yaghmaie M, et al
    Minimal residual disease (MRD) detection using rearrangement of immunoglobulin/T cell receptor genes in adult patients with acute lymphoblastic leukemia (ALL).
    Ann Hematol. 2018 Feb 1. pii: 10.1007/s00277-018-3230.
    PubMed     Text format     Abstract available


  168. CHAN TSY, Kwong YL
    Systemic trichosporonosis mimicking disseminated varicella zoster viral infection during blinatumomab therapy.
    Ann Hematol. 2018;97:371-373.
    PubMed     Text format    


    January 2018
  169. SAEED OAM, Longe HO, Zhou J
    T cell large granular lymphocytic leukemia, a rare form of post lung transplant lymphoproliferative disorder.
    Ann Hematol. 2018 Jan 8. pii: 10.1007/s00277-017-3213.
    PubMed     Text format    


  170. BEN LAKHAL R, Ghedira H, Bellaaj H, Ben Youssef Y, et al
    Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
    Ann Hematol. 2018 Jan 6. pii: 10.1007/s00277-017-3224.
    PubMed     Text format     Abstract available


  171. KAMEDA K, Kako S, Hayakawa J, Akahoshi Y, et al
    Safety of avoiding systemic corticosteroid administration for grade II acute graft-versus-host disease limited to the skin.
    Ann Hematol. 2018;97:169-179.
    PubMed     Text format     Abstract available


    December 2017
  172. ZHAO H, Zhao Y, Zhang Y, Hou J, et al
    Difference in causes and prognostic factors of early death between cohorts with de novo and relapsed acute promyelocytic leukemia.
    Ann Hematol. 2017 Dec 30. pii: 10.1007/s00277-017-3216.
    PubMed     Text format     Abstract available


  173. SADEGHI N, Li HC
    MRD-negative complete remission in relapsed refractory hairy cell leukemia with bendamustine and obinutuzumab.
    Ann Hematol. 2017 Dec 28. pii: 10.1007/s00277-017-3219.
    PubMed     Text format    


  174. YANG J, Cai Y, Jiang J, Wan L, et al
    Early tapering of immunosuppressive agents after HLA-matched donor transplantation can improve the survival of patients with advanced acute myeloid leukemia.
    Ann Hematol. 2017 Dec 18. pii: 10.1007/s00277-017-3204.
    PubMed     Text format     Abstract available


  175. HARADA K, Doki N, Hagino T, Miyawaki S, et al
    Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201.
    Ann Hematol. 2017 Dec 2. pii: 10.1007/s00277-017-3156.
    PubMed     Text format     Abstract available


    November 2017
  176. HILMI M, Bally C, Burns R, Lorillon G, et al
    Favorable evolution of lung interstitial disease in a patient with chronic myelomonocytic leukemia treated with azacitidine.
    Ann Hematol. 2017 Nov 23. pii: 10.1007/s00277-017-3190.
    PubMed     Text format    


  177. HASSANI S, Khaleghian A, Ahmadian S, Alizadeh S, et al
    Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4).
    Ann Hematol. 2017 Nov 20. doi: 10.1007/s00277-017-3163.
    PubMed     Text format     Abstract available


  178. PRATS-MARTIN C, Jimenez-Guerrero P, Morales-Camacho RM, Caballero-Velazquez T, et al
    KIT D816V- chronic myelomonocytic leukemia progressing to KIT D816V+ associated to mast cell leukemia responding to allogeneic hematopoietic cell transplantation.
    Ann Hematol. 2017 Nov 18. doi: 10.1007/s00277-017-3187.
    PubMed     Text format    


  179. SHAO H, Yang Q, Zhang P, Liu H, et al
    Simultaneous occurrence of two distinct leukemic clones with PML-RARalpha and RUNX1-RUNX1T1 in a case of acute myeloid leukemia.
    Ann Hematol. 2017 Nov 9. doi: 10.1007/s00277-017-3169.
    PubMed     Text format    


  180. LORENZANA N, Avila LF, Alonso S, Colado E, et al
    The impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment.
    Ann Hematol. 2017;96:1833-1840.
    PubMed     Text format     Abstract available


    October 2017
  181. NASSEREDDINE S, Lap CJ, Haroun F, Tabbara I, et al
    The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.
    Ann Hematol. 2017 Oct 31. doi: 10.1007/s00277-017-3161.
    PubMed     Text format     Abstract available


  182. NAGEL G, Weber D, Fromm E, Erhardt S, et al
    Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).
    Ann Hematol. 2017 Oct 31. doi: 10.1007/s00277-017-3150.
    PubMed     Text format     Abstract available


  183. YANG D, Zhang X, Zhang X, Xu Y, et al
    The progress and current status of immunotherapy in acute myeloid leukemia.
    Ann Hematol. 2017 Oct 28. doi: 10.1007/s00277-017-3148.
    PubMed     Text format     Abstract available


  184. ZHANG X, Li B, Yu J, Dahlstrom J, et al
    MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia.
    Ann Hematol. 2017 Oct 27. doi: 10.1007/s00277-017-3158.
    PubMed     Text format     Abstract available


  185. KHAN M, Siddiqi R, Thompson PA
    Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies.
    Ann Hematol. 2017 Oct 23. doi: 10.1007/s00277-017-3149.
    PubMed     Text format     Abstract available


  186. GUTIERREZ-AGUIRRE CH, Flores-Jimenez JA, Alatorre-Ricardo J, Cantu-Rodriguez OG, et al
    The prognostic significance of serum XCL1 concentration in patients with acute lymphoblastic leukemia: a pilot study.
    Ann Hematol. 2017 Oct 13. doi: 10.1007/s00277-017-3142.
    PubMed     Text format     Abstract available


  187. TERADA K, Yamaguchi H, Ueki T, Usuki K, et al
    Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor.
    Ann Hematol. 2017 Oct 4. doi: 10.1007/s00277-017-3143.
    PubMed     Text format     Abstract available


  188. IURLO A, Galimberti S, Abruzzese E, Annunziata M, et al
    Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.
    Ann Hematol. 2017 Oct 2. doi: 10.1007/s00277-017-3144.
    PubMed     Text format     Abstract available


  189. YANAGIHARA T, Ikematsu Y, Kato K, Yonekawa A, et al
    Expression of PD-1 and PD-L1 on cytotoxic T lymphocytes and immune deficiency in a patient with adult T cell leukemia/lymphoma.
    Ann Hematol. 2017 Oct 2. doi: 10.1007/s00277-017-3146.
    PubMed     Text format    


  190. SAMADI O, Breunis H, Sandoval J, Akilan K, et al
    Return to work and work-related disability among AML survivors.
    Ann Hematol. 2017;96:1625-1633.
    PubMed     Text format     Abstract available


  191. HANSSON L, Asklid A, Diels J, Eketorp-Sylvan S, et al
    Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia.
    Ann Hematol. 2017;96:1681-1691.
    PubMed     Text format     Abstract available


  192. HAMADOU WS, Mani R, Besbes S, Bourdon V, et al
    GATA2 gene analysis in several forms of hematological malignancies including familial aggregations.
    Ann Hematol. 2017;96:1635-1639.
    PubMed     Text format     Abstract available


    September 2017
  193. HOU J, Wang S, Zhang Y, Fan D, et al
    Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide.
    Ann Hematol. 2017 Sep 22. doi: 10.1007/s00277-017-3130.
    PubMed     Text format     Abstract available


  194. JAWHAR M, Naumann N, Schwaab J, Baurmann H, et al
    Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.
    Ann Hematol. 2017;96:1463-1470.
    PubMed     Text format     Abstract available


  195. HAROUN F, Solola SA, Nassereddine S, Tabbara I, et al
    PD-1 signaling and inhibition in AML and MDS.
    Ann Hematol. 2017;96:1441-1448.
    PubMed     Text format     Abstract available


    August 2017
  196. SHAO H, Yang Q, Wu C, Cen J, et al
    Therapy-related acute myeloid leukemia with inv(16) after successful therapy for de novo acute myeloid leukemia with t(8;21).
    Ann Hematol. 2017 Aug 24. doi: 10.1007/s00277-017-3110.
    PubMed     Text format    


  197. OH SB, Park SW, Chung JS, Lee WS, et al
    Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy.
    Ann Hematol. 2017 Aug 21. doi: 10.1007/s00277-017-3104.
    PubMed     Text format     Abstract available


  198. IURLO A, Bucelli C, Cattaneo D, Orofino N, et al
    Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia.
    Ann Hematol. 2017 Aug 19. doi: 10.1007/s00277-017-3105.
    PubMed     Text format    


  199. LOU Y, Ma Y, Sun J, Suo S, et al
    Effectivity of a modified Sanz risk model for early death prediction in patients with newly diagnosed acute promyelocytic leukemia.
    Ann Hematol. 2017 Aug 19. doi: 10.1007/s00277-017-3096.
    PubMed     Text format     Abstract available


  200. ZHAO Y, Wang J, Luo Y, Shi J, et al
    Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia.
    Ann Hematol. 2017;96:1353-1360.
    PubMed     Text format     Abstract available


  201. SAGLIO G, le Coutre P, Cortes J, Mayer J, et al
    Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.
    Ann Hematol. 2017;96:1303-1313.
    PubMed     Text format     Abstract available


  202. EREN R, Dogu MH, Emir S, Huq GE, et al
    Rethinking the usefulness of bone marrow biopsy on treatment decision in CLL patients at diagnosis.
    Ann Hematol. 2017;96:1315-1321.
    PubMed     Text format     Abstract available


    July 2017
  203. YUI S, Kurosawa S, Yamaguchi H, Kanamori H, et al
    D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations.
    Ann Hematol. 2017 Jul 31. doi: 10.1007/s00277-017-3074.
    PubMed     Text format     Abstract available


  204. NISCOLA P, Tendas A, Abruzzese E, Caravita T, et al
    Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice.
    Ann Hematol. 2017 Jul 12. doi: 10.1007/s00277-017-3064.
    PubMed     Text format    


  205. THOMAY K, Fedder C, Hofmann W, Kreipe H, et al
    Telomere shortening, TP53 mutations and deletions in chronic lymphocytic leukemia result in increased chromosomal instability and breakpoint clustering in heterochromatic regions.
    Ann Hematol. 2017 Jul 9. doi: 10.1007/s00277-017-3055.
    PubMed     Text format     Abstract available


  206. VENTURA FERREIRA MS, Crysandt M, Ziegler P, Hummel S, et al
    Evidence for a pre-existing telomere deficit in non-clonal hematopoietic stem cells in patients with acute myeloid leukemia.
    Ann Hematol. 2017 Jul 3. doi: 10.1007/s00277-017-3049.
    PubMed     Text format     Abstract available


  207. RODRIGUEZ-VEIGA R, Igual B, Montesinos P, Tormo M, et al
    Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin.
    Ann Hematol. 2017;96:1077-1084.
    PubMed     Text format     Abstract available


  208. KAUR V, Swami A
    Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
    Ann Hematol. 2017;96:1175-1184.
    PubMed     Text format     Abstract available


    June 2017
  209. URESHINO H, Kamachi K, Miyahara M
    Detection of human T-cell lymphotropic virus type I-specific cytotoxic T-cells may predict treatment responses in adult T-cell leukemia/lymphoma patients.
    Ann Hematol. 2017 Jun 27. doi: 10.1007/s00277-017-3052.
    PubMed     Text format    


  210. BALDUCCI E, Nivaggioni V, Boudjarane J, Bouriche L, et al
    Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy.
    Ann Hematol. 2017 Jun 20. doi: 10.1007/s00277-017-3050.
    PubMed     Text format    


  211. HEUSER M, Gabdoulline R, Loffeld P, Dobbernack V, et al
    Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.
    Ann Hematol. 2017 Jun 13. doi: 10.1007/s00277-017-3027.
    PubMed     Text format     Abstract available


  212. JONSSON S, Olsson B, Soderberg J, Wadenvik H, et al
    Erratum to: Good adherence to imatinib therapy among patients with chronic myeloid leukemia-a single-center observational study.
    Ann Hematol. 2017 Jun 9. doi: 10.1007/s00277-017-3024.
    PubMed     Text format    


  213. DE LACERDA MP, Guedes NR, Yamakawa PE, Pereira AD, et al
    Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with (del17p).
    Ann Hematol. 2017 Jun 9. doi: 10.1007/s00277-017-3039.
    PubMed     Text format    


  214. ABLA O, Ribeiro RC, Testi AM, Montesinos P, et al
    Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy.
    Ann Hematol. 2017 Jun 8. doi: 10.1007/s00277-017-3042.
    PubMed     Text format     Abstract available


  215. MUKHERJEE S, Ibrahimi S, John S, Adnan MM, et al
    Non-seminomatous mediastinal germ cell tumor and acute megakaryoblastic leukemia.
    Ann Hematol. 2017 Jun 3. doi: 10.1007/s00277-017-3037.
    PubMed     Text format     Abstract available


  216. OKA S, Ono K, Nohgawa M
    Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation.
    Ann Hematol. 2017 Jun 2. doi: 10.1007/s00277-017-3032.
    PubMed     Text format    


  217. BRAULKE F, Schulz X, Germing U, Schuler E, et al
    Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.
    Ann Hematol. 2017;96:887-894.
    PubMed     Text format     Abstract available


  218. CHOI DC, Tremblay D, Iancu-Rubin C, Mascarenhas J, et al
    Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms.
    Ann Hematol. 2017;96:919-927.
    PubMed     Text format     Abstract available


    May 2017
  219. GONG Z, Zheng L, Tang Z, Chen Z, et al
    Erratum to: Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Ann Hematol. 2017 May 20. doi: 10.1007/s00277-017-3025.
    PubMed     Text format    


  220. HAEN SP, Groh C, Schumm M, Backert L, et al
    Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation.
    Ann Hematol. 2017;96:817-827.
    PubMed     Text format     Abstract available


    April 2017
  221. MATERN S, Schmidt E, Hartmann D, Schliemann C, et al
    Successful second allogeneic stem cell transplantation in a patient with T-lymphoblastic leukemia (T-ALL) relapsed as myeloid sarcoma.
    Ann Hematol. 2017 Apr 27. doi: 10.1007/s00277-017-3000.
    PubMed     Text format    


  222. SANCHEZ R, Ayala R, Alonso RA, Martinez MP, et al
    Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid.
    Ann Hematol. 2017 Apr 27. doi: 10.1007/s00277-017-3002.
    PubMed     Text format     Abstract available


  223. KOYA J, Ibaraki T, Yamazaki I, Nakamura F, et al
    Acute basophilic leukemia with add(3)(q12) accompanied by histamine excess symptoms.
    Ann Hematol. 2017 Apr 19. doi: 10.1007/s00277-017-2987.
    PubMed     Text format    


  224. ESPINOSA LARA P, Quiros Redondo V, Aguado Lobo M, Jimenez-Reyes J, et al
    Purpuric exanthema in a patient with hairy cell leukemia treated with cladribine and allopurinol.
    Ann Hematol. 2017 Apr 8. doi: 10.1007/s00277-017-2992.
    PubMed     Text format    


  225. SHUSTIK C, Bence-Bruckler I, Delage R, Owen CJ, et al
    Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.
    Ann Hematol. 2017 Apr 7. doi: 10.1007/s00277-017-2982.
    PubMed     Text format     Abstract available


    March 2017
  226. DUNOYER-GEINDRE S, Rivier-Cordey AS, Tsopra O, Lecompte T, et al
    Effect of ATRA and ATO on the expression of tissue factor in NB4 acute promyelocytic leukemia cells and regulatory function of the inflammatory cytokines TNF and IL-1beta.
    Ann Hematol. 2017 Mar 25. doi: 10.1007/s00277-017-2970.
    PubMed     Text format     Abstract available


  227. BOTH A, Krauter J, Damm F, Thol F, et al
    The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia.
    Ann Hematol. 2017 Mar 22. doi: 10.1007/s00277-017-2967.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: